Study summary

Tirzepatide lowered heart failure events in people with obesity and HFpEF

SUMMIT trial (tirzepatide) · 731 people, phase 3 · Published November 2024, New England Journal of Medicine

9.9%had cardiovascular death or worsening heart failure, vs 15.3% with placebo

What was tested

Weekly tirzepatide against placebo in heart failure with preserved ejection fraction (50% or more) and obesity.

What they found

What it means

Weight-loss drugs are now part of treating obesity-related HFpEF.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.